Immune System News and Research

RSS

New blood test to determine patients at low risk for rejection of transplanted hearts

After his heart transplant in 2005, Ramon Llenado underwent a biopsy every week, then every month, then every three months. Most heart transplant patients face a lifetime of these invasive tests, which involve snipping out tiny pieces of heart to check for possible organ rejection.

23 Apr 2010

New multi-faceted treatment program for young adults addicted to opioid drugs

A multi-faceted treatment program for young adults addicted to opioid drugs was unveiled today at the National Institute on Drug Abuse's Blending Conference in Albuquerque, N.M. This eighth meeting in the series brings together researchers and clinicians so their latest findings can be immediately applied to the needs of patients and their families dealing with addictive disorders.

23 Apr 2010

Researchers produce stem cells from eggs of aging mice for regenerative medicine

Researchers at NYU Langone Medical Center have created stem cells from the eggs of aging mice that could be used for reproductive purposes and regenerative medicine. The study, published in April issue of Aging Cell, found that even though the eggs from older females were slightly less efficient at making stem cells than those from younger females, the capacity to create stem cells was sustained.

23 Apr 2010

Mayo Clinic study finds changes in tissue damage throughout the course of MS

A new Mayo Clinic study has found that the type of tissue damage changes throughout the course of multiple sclerosis. In early relapsing disease stages, the plaques, or areas where the nervous system is inflamed or demyelinated, are predominantly active with distinct heterogeneous patterns of myelin damage.

23 Apr 2010

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.

23 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

Genetic tests that may replace biopsies

Genetic tests conducted on blood samples may replace the current biopsies when it comes to checking if immune systems are rejecting new organs of heart transplant patients. The test would be far less invasive and uncomfortable as compared to the biopsies, not to mention more affordable.

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product.

23 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

22 Apr 2010

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

For some years now a small group of scientists have been pioneering a revolutionary idea - that the vertebrate immune system could have a role in the regulation of iron in the body. And now, a work soon to be published in the journal Immunology, shows that human lymphocytes (white blood cells) actually produce hepcidin, the most important protein in the regulation of iron levels in the body.

22 Apr 2010

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Promising research brings hope for the almost two thousand lung transplant candidates who currently make up The United Network for Organ Sharing's (UNOS) wait list. A new technique that uses gene therapy to help repair damaged lungs previously found unfit for transplant shows promise for addressing the critical shortage of healthy donor organs.

22 Apr 2010

Death protein ubiquitin binds to and activates RIG-I: UT Southwestern researchers

UT Southwestern Medical Center researchers have determined how a protein that normally latches onto molecules inside cells and marks them for destruction also gives life to the body's immune response against viruses.

22 Apr 2010

Age delays time taken for recovery of sense of taste following nerve injury

Age dramatically delays the time if takes to recover the sense of taste following a significant nerve injury, Medical College of Georgia researchers said.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

People with vitiligo may have less risk of developing malignant melanoma: Research

People with the skin pigmentation disorder vitiligo may have less risk of developing life-threatening malignant melanoma, according to new research. The study also further confirms the suspicion that vitiligo is an autoimmune disease, which occur when the body's immune system reacts against its own tissues or organs.

22 Apr 2010

Immune System News and Research

New blood test to determine patients at low risk for rejection of transplanted hearts

New multi-faceted treatment program for young adults addicted to opioid drugs

Researchers produce stem cells from eggs of aging mice for regenerative medicine

Mayo Clinic study finds changes in tissue damage throughout the course of MS

TUM scientists collaborate with Fujitsu Laboratories of Japan to commercialize biosensor chip

BUSM professor receives Individual Biomedical Research Award

Genetic tests that may replace biopsies

IAVI, Lentigen to design preventive AIDS vaccine

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Death protein ubiquitin binds to and activates RIG-I: UT Southwestern researchers

Age delays time taken for recovery of sense of taste following nerve injury

ImmunoCellular Therapeutics, UPENN sign research agreement

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

People with vitiligo may have less risk of developing malignant melanoma: Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News